Windtree Therapeutics, Inc. Repayment/Issuance of Debt (Net)

Repayment/Issuance of Debt (Net) of WINT for past 10 years: annual, quarterly and twelve month trailing (TTM) including Repayment/Issuance of Debt (Net) growth rates and interactive chart.


Highlights and Quick Summary

  • Repayment/Issuance of Debt (Net) for the quarter ending June 29, 2020 was $1 Million (a -602.51% decrease compared to previous quarter)
  • Year-over-year quarterly Repayment/Issuance of Debt (Net) decreased by -389.02%
  • Annual Repayment/Issuance of Debt (Net) for 2019 was $-1.06 Million (a -117.72% decrease from previous year)
  • Annual Repayment/Issuance of Debt (Net) for 2018 was $6 Million (a 53.85% increase from previous year)
  • Annual Repayment/Issuance of Debt (Net) for 2017 was $3.9 Million (a -85.85% decrease from previous year)
  • Twelve month Repayment/Issuance of Debt (Net) ending June 29, 2020 was $212 Thousand (a -126.01% decrease compared to previous quarter)
  • Twelve month trailing Repayment/Issuance of Debt (Net) decreased by -135.33% year-over-year
Trailing Repayment/Issuance of Debt (Net) for the last four month:
29 Jun '20 30 Mar '20 30 Dec '19 29 Sep '19
$212 Thousand $-815 Thousand $-1.06 Million $-600 Thousand
Visit stockrow.com/WINT for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Repayment/Issuance of Debt (Net) of Windtree Therapeutics, Inc.

Most recent Repayment/Issuance of Debt (Net)of WINT including historical data for past 10 years.

Interactive Chart of Repayment/Issuance of Debt (Net) of Windtree Therapeutics, Inc.

Windtree Therapeutics, Inc. Repayment/Issuance of Debt (Net) for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 $1.0 $-0.2
2019 $-0.24 $-0.35 $-0.03 $-0.45 $-1.06
2018 $0.22 $3.28 $0.0 $2.5 $6.0
2017 $1.3 $2.6 $3.9
2015 $0.0 $27.61 $-0.02 $-0.02 $27.57
2014 $-0.02 $-0.02 $-0.02 $-0.02 $-0.08
2013 $75.79 $-0.02 $15.09 $9.83 $100.7
2012 $-0.07 $-0.02 $-0.02 $43.58 $43.48
2011 $0.32 $-0.04 $-0.05 $22.55 $22.78
2010 $1.16 $-3.69 $6.49 $14.89 $18.84

Business Profile of Windtree Therapeutics, Inc.

Sector: Medical
Industry: Drugs
Windtree Therapeutics, Inc., a biotechnology and medical device company, engages in the research and development of products that focus on acute pulmonary and cardiovascular diseases. Its four lead development programs include istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as in Phase 2a clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase 2b clinical trial to treat respiratory distress syndrome (RDS) in premature infants; lyophilized KL4 surfactant for the treatment of lung injury resulting from COVID-19; and Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was incorporated in 1992 and is headquartered in Warrington, Pennsylvania.